These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Moyamoya disease patient mutations in the RING domain of RNF213 reduce its ubiquitin ligase activity and enhance NFκB activation and apoptosis in an AAA+ domain-dependent manner. Takeda M; Tezuka T; Kim M; Choi J; Oichi Y; Kobayashi H; Harada KH; Mizushima T; Taketani S; Koizumi A; Youssefian S Biochem Biophys Res Commun; 2020 May; 525(3):668-674. PubMed ID: 32139119 [TBL] [Abstract][Full Text] [Related]
3. A new horizon of moyamoya disease and associated health risks explored through RNF213. Koizumi A; Kobayashi H; Hitomi T; Harada KH; Habu T; Youssefian S Environ Health Prev Med; 2016 Mar; 21(2):55-70. PubMed ID: 26662949 [TBL] [Abstract][Full Text] [Related]
4. Importance of RNF213 polymorphism on clinical features and long-term outcome in moyamoya disease. Kim EH; Yum MS; Ra YS; Park JB; Ahn JS; Kim GH; Goo HW; Ko TS; Yoo HW J Neurosurg; 2016 May; 124(5):1221-7. PubMed ID: 26430847 [TBL] [Abstract][Full Text] [Related]
5. Moyamoya disease factor RNF213 is a giant E3 ligase with a dynein-like core and a distinct ubiquitin-transfer mechanism. Ahel J; Lehner A; Vogel A; Schleiffer A; Meinhart A; Haselbach D; Clausen T Elife; 2020 Jun; 9():. PubMed ID: 32573437 [TBL] [Abstract][Full Text] [Related]
6. RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance. Zhang Q; Liu Y; Zhang D; Wang R; Zhang Y; Wang S; Yu L; Lu C; Liu F; Zhou J; Zhang X; Zhao J J Neurosurg; 2017 Apr; 126(4):1106-1113. PubMed ID: 27128593 [TBL] [Abstract][Full Text] [Related]
7. Rare variants of RNF213 and moyamoya/non-moyamoya intracranial artery stenosis/occlusion disease risk: a meta-analysis and systematic review. Liao X; Deng J; Dai W; Zhang T; Yan J Environ Health Prev Med; 2017 Nov; 22(1):75. PubMed ID: 29165161 [TBL] [Abstract][Full Text] [Related]
8. RNF213 p.R4810K Polymorphism and the Risk of Moyamoya Disease, Intracranial Major Artery Stenosis/Occlusion, and Quasi-Moyamoya Disease: A Meta-Analysis. Wang Y; Mambiya M; Li Q; Yang L; Jia H; Han Y; Liu W J Stroke Cerebrovasc Dis; 2018 Aug; 27(8):2259-2270. PubMed ID: 29752070 [TBL] [Abstract][Full Text] [Related]
9. The Role of RNF213 4810G>A and 4950G>A Variants in Patients with Moyamoya Disease in Korea. Park YS; An HJ; Kim JO; Kim WS; Han IB; Kim OJ; Kim NK; Kim DS Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29160859 [TBL] [Abstract][Full Text] [Related]
10. Biochemical and Functional Characterization of RNF213 (Mysterin) R4810K, a Susceptibility Mutation of Moyamoya Disease, in Angiogenesis In Vitro and In Vivo. Kobayashi H; Matsuda Y; Hitomi T; Okuda H; Shioi H; Matsuda T; Imai H; Sone M; Taura D; Harada KH; Habu T; Takagi Y; Miyamoto S; Koizumi A J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26126547 [TBL] [Abstract][Full Text] [Related]
11. In silico explanation for the causalities of deleterious RNF213 SNPs in Moyamoya disease and insulin resistance. Sarkar P; Thirumurugan K Comput Biol Chem; 2021 Jun; 92():107488. PubMed ID: 33930741 [TBL] [Abstract][Full Text] [Related]
12. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. Liu W; Morito D; Takashima S; Mineharu Y; Kobayashi H; Hitomi T; Hashikata H; Matsuura N; Yamazaki S; Toyoda A; Kikuta K; Takagi Y; Harada KH; Fujiyama A; Herzig R; Krischek B; Zou L; Kim JE; Kitakaze M; Miyamoto S; Nagata K; Hashimoto N; Koizumi A PLoS One; 2011; 6(7):e22542. PubMed ID: 21799892 [TBL] [Abstract][Full Text] [Related]
13. Genetic analysis of Tashiro R; Fujimura M; Sakata H; Endo H; Tomata Y; Sato-Maeda M; Niizuma K; Tominaga T Neurol Res; 2019 Sep; 41(9):811-816. PubMed ID: 31064275 [No Abstract] [Full Text] [Related]
14. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. Kamada F; Aoki Y; Narisawa A; Abe Y; Komatsuzaki S; Kikuchi A; Kanno J; Niihori T; Ono M; Ishii N; Owada Y; Fujimura M; Mashimo Y; Suzuki Y; Hata A; Tsuchiya S; Tominaga T; Matsubara Y; Kure S J Hum Genet; 2011 Jan; 56(1):34-40. PubMed ID: 21048783 [TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of RNF213 gene for moyamoya disease in the Chinese Han population. Wu Z; Jiang H; Zhang L; Xu X; Zhang X; Kang Z; Song D; Zhang J; Guan M; Gu Y PLoS One; 2012; 7(10):e48179. PubMed ID: 23110205 [TBL] [Abstract][Full Text] [Related]
16. Role of the Kim HJ; Choi EH; Chung JW; Kim JH; Kim YS; Seo WK; Kim GM; Bang OY J Am Heart Assoc; 2021 Jan; 10(1):e017660. PubMed ID: 33356381 [TBL] [Abstract][Full Text] [Related]
17. Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects. Wang X; Zhang Z; Liu W; Xiong Y; Sun W; Huang X; Jiang Y; Ni G; Sun W; Zhou L; Wu L; Zhu W; Li H; Liu X; Xu G Gene; 2013 Sep; 526(2):437-42. PubMed ID: 23769926 [TBL] [Abstract][Full Text] [Related]
18. RNF213 rs112735431 polymorphism in intracranial artery steno-occlusive disease and moyamoya disease in Koreans. Park MG; Shin JH; Lee SW; Park HR; Park KP J Neurol Sci; 2017 Apr; 375():331-334. PubMed ID: 28320162 [TBL] [Abstract][Full Text] [Related]
19. Ok T; Jung YH; Kim J; Park SK; Park G; Lee S; Lee KY J Am Heart Assoc; 2022 Aug; 11(15):e025676. PubMed ID: 35876407 [TBL] [Abstract][Full Text] [Related]
20. Temporal profile of magnetic resonance angiography and decreased ratio of regulatory T cells after immunological adjuvant administration to mice lacking RNF213, a susceptibility gene for moyamoya disease. Kanoke A; Fujimura M; Niizuma K; Fujimura T; Kakizaki A; Ito A; Sakata H; Sato-Maeda M; Kure S; Tominaga T Brain Res; 2016 Jul; 1642():1-9. PubMed ID: 26972532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]